Hualan Biotech announced on September 23 that the company's shareholding company Hualan Ankang Biology Co., Ltd. applied for marketing license for injectable trastuzumab and obtained a “Notice of Acceptance” issued by the State Drug Administration. Injectable trastuzumab is a monoclonal antibody targeting HER2. The original product name Herceptin is a core first-line drug for the treatment of HER2-positive breast cancer and gastric cancer. Drug indications: HER2 positive early-stage breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Hualan Biotech announced on September 23 that the company's shareholding company Hualan Ankang Biology Co., Ltd. applied for marketing license for injectable trastuzumab and obtained a “Notice of Acceptance” issued by the State Drug Administration. Injectable trastuzumab is a monoclonal antibody targeting HER2. The original product name Herceptin is a core first-line drug for the treatment of HER2-positive breast cancer and gastric cancer. Drug indications: HER2 positive early-stage breast cancer, metastatic breast cancer, and metastatic gastric cancer.